The atherosclerotic cardiovascular disease market in the 7MM is expected to show positive growth during the forecast period (2025–2034), mainly attributed to the launch of upcoming therapies such as ...

Cardiovascular disease is the leading cause of death worldwide and often originates in atherosclerosis, a chronic condition in which inflammation and fat deposits cause arteries to harden and narrow.

GLP-1RA therapy significantly reduces the risk for new-onset heart failure in patients with T2D or obesity, regardless of weight loss.

Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Medical illustration showing how plaque buildup and clot formation can restrict blood flow in arteries. Researchers have developed a luteolin-based nanomedicine that targets and stabilizes these ...

A new AI tool can rapidly evaluate data from echocardiography, an imaging test commonly used to diagnose heart disease, according to new research led by Cedars-Sinai. The study, published in JACC, ...

Iván Fernández-López, Diego Mañanes, Ana Redondo-Urzainqui, Miguel Galán, Sarai Martínez-Cano, Marcos Femenía-Muiña, Vanessa Núñez, Eleftheria Papaioannou, Alessia Ferrarini, Coral Barbas, Annalaura ...

Neratinib, an oral drug commonly used in the treatment of breast cancer, has shown potential in reducing vascular ...

Researchers from the University of Southern Denmark and Odense University Hospital have studied tissue from patients with atherosclerosis. They found that many of the cells in the diseased tissue ...